



Preeclampsia or Placenta Previa; Extravillous Trophoblast Cells Are Determinative

Nadia Sheibak ^{1,*}

¹Department of Histology, School of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran

*Corresponding author: Department of Histology, School of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran. Tel: +98-5433295794, Email: nadia1989sh@yahoo.com

Received 2019 January 21; **Revised** 2019 February 03; **Accepted** 2019 February 03.

Keywords: Extravillous Trophoblast, Placenta Previa, Preeclampsia, Pregnancy Complications

Dear Editor,

Placenta previa (PP) probably inhibits the development of preeclampsia (PE) during pregnancy (1, 2) and the presence of PE decreases the incidence of PP (2, 3). It could be because of different etiologies and mechanisms of PP against PE (1, 3).

PE is defined as a hypertensive disease during pregnancy that is related to a disorder in the placenta and vascular endothelium (1, 4). PP is the obstruction of the internal os of the cervix by the abnormally implanted placenta (2, 5).

In a study, it was observed that the uteroplacental blood flow decreased significantly in the PE group while there was an increased uteroplacental blood flow in the PP group (3, 6). These changes result from adaptive processes in the abnormally implanted placenta to provide enough and safe perfusion of the placenta. The increased blood flow in PP subjects could be due to the implantation of the placenta in the lower segment of the uterus. The lack of visceral congestion in the lower part of uterine in PP might prevent PE incidence and hypertension during pregnancy (2, 3). In PE, the placenta is implanted superficially and results in insufficient blood flow if combined with a disorder in the vascular endothelium (1, 7).

Extravillous trophoblast cells (EVTs) are responsible for blood circulation supply in the placenta by remodeling of uterine spiral arteries (7, 8). EVT's invade into the uterine wall during the implantation and development of the placenta. This regulated process is very critical during normal pregnancy and its impairment leads to pregnancy complications (8, 9).

EVT's invasion converts spiral arteries to large vessels with reduced resistance that subsequently increases placental perfusion. Therefore, decreased blood flow in the

uteroplacental circulation of PE pregnancies compared to normal placentas could be due to the shallow invasion of EVT's, resulting in the conversion of spiral arteries to narrow vessels and superficial implantation of the placenta (6, 9).

In PP pregnancies, deep implantation of placenta leads to sufficient oxygen supply. On the contrary, hypoxia has been reported in PE placentas (2, 3). Superficially implanted placenta and defected vascular endothelium are not likely able to provide enough oxygen required for normal development of placenta (2, 9). Hypoxia has been reported as the main factor for the progression of pregnancy complications (8).

In a normal pregnancy, the immune response of the mother to fetus is regulated conservatively. It has been shown that the maternal immune system is aggravated in PE pregnancies (4). A possible mechanism for the development of PE is the presence of angiogenesis-related factors and mediators of inflammation in the mother's bloodstream as an immunological reaction, leading to maternal vascular disorders during pregnancy (1, 10).

According to the above-mentioned statements, it can be supposed that because of different mechanisms of PP and PE pathogenesis (3), EVT's invade differently into the decidua and the invasion leads to different development of the placenta in these conditions (8).

Therefore, the investigation of EVT's in placentas of complicated pregnancies could be the subject of further studies. Stereological techniques could be useful to test the hypothesis that the number of EVT's is altered in samples from PP complicated pregnancies compared to PE placentas (5, 8).

Footnotes

Conflict of Interests: The author has no conflict of interests to declare.

Funding/Support: The author of this paper acknowledges the Zahedan University of Medical Sciences (ZAUMS) that assisted in the development of the projects related to this issue.

References

1. Adam I, Haggaz AD, Mirghani OA, Elhassan EM. Placenta previa and pre-eclampsia: Analyses of 1645 cases at medani maternity hospital, Sudan. *Front Physiol.* 2013;**4**:32. doi: [10.3389/fphys.2013.00032](https://doi.org/10.3389/fphys.2013.00032). [PubMed: [23450096](https://pubmed.ncbi.nlm.nih.gov/23450096/)]. [PubMed Central: [PMC3584291](https://pubmed.ncbi.nlm.nih.gov/PMC3584291/)].
2. Faiz AS, Ananth CV. Etiology and risk factors for placenta previa: An overview and meta-analysis of observational studies. *J Matern Fetal Neonatal Med.* 2003;**13**(3):175-90. doi: [10.1080/jmf.13.3.175.190](https://doi.org/10.1080/jmf.13.3.175.190). [PubMed: [12820840](https://pubmed.ncbi.nlm.nih.gov/12820840/)].
3. Ying H, Lu Y, Dong YN, Wang DF. Effect of placenta previa on preeclampsia. *PLoS One.* 2016;**11**(1). e0146126. doi: [10.1371/journal.pone.0146126](https://doi.org/10.1371/journal.pone.0146126). [PubMed: [26731265](https://pubmed.ncbi.nlm.nih.gov/26731265/)]. [PubMed Central: [PMC4701488](https://pubmed.ncbi.nlm.nih.gov/PMC4701488/)].
4. Pinheiro MB, Gomes KB, Ronda CR, Guimaraes GG, Freitas LG, Teixeira-Carvalho A, et al. Severe preeclampsia: Association of genes polymorphisms and maternal cytokines production in Brazilian population. *Cytokine.* 2015;**71**(2):232-7. doi: [10.1016/j.cyto.2014.10.021](https://doi.org/10.1016/j.cyto.2014.10.021). [PubMed: [25461403](https://pubmed.ncbi.nlm.nih.gov/25461403/)].
5. Heidari Z, Sakhavar N, Mahmoudzadeh-Sagheb H, Ezazi-Bojnourdi T. Stereological analysis of human placenta in cases of placenta previa in comparison with normally implanted controls. *J Reprod Infertil.* 2015;**16**(2):90-5. [PubMed: [25927025](https://pubmed.ncbi.nlm.nih.gov/25927025/)]. [PubMed Central: [PMC4386091](https://pubmed.ncbi.nlm.nih.gov/PMC4386091/)].
6. Lash GE, Otun HA, Innes BA, Kirkley M, De Oliveira L, Searle RF, et al. Interferon-gamma inhibits extravillous trophoblast cell invasion by a mechanism that involves both changes in apoptosis and protease levels. *FASEB J.* 2006;**20**(14):2512-8. doi: [10.1096/fj.06-6616com](https://doi.org/10.1096/fj.06-6616com). [PubMed: [17142800](https://pubmed.ncbi.nlm.nih.gov/17142800/)].
7. Banerjee S, Smallwood A, Moorhead J, Chambers AE, Papageorghiou A, Campbell S, et al. Placental expression of interferon-gamma (IFN-gamma) and its receptor IFN-gamma R2 fail to switch from early hypoxic to late normotensive development in preeclampsia. *J Clin Endocrinol Metab.* 2005;**90**(2):944-52. doi: [10.1210/jc.2004-1113](https://doi.org/10.1210/jc.2004-1113). [PubMed: [15585559](https://pubmed.ncbi.nlm.nih.gov/15585559/)].
8. Sheibak N. The role of hypoxia in normal pregnancy and pregnancy complications. *Gene Cell Tissue.* 2018;**5**(2). doi: [10.5812/gct.80202](https://doi.org/10.5812/gct.80202).
9. Lockwood CJ, Basar M, Kayisli UA, Guzeloglu-Kayisli O, Murk W, Wang J, et al. Interferon-gamma protects first-trimester decidual cells against aberrant matrix metalloproteinases 1, 3, and 9 expression in preeclampsia. *Am J Pathol.* 2014;**184**(9):2549-59. doi: [10.1016/j.ajpath.2014.05.025](https://doi.org/10.1016/j.ajpath.2014.05.025). [PubMed: [25065683](https://pubmed.ncbi.nlm.nih.gov/25065683/)]. [PubMed Central: [PMC4188280](https://pubmed.ncbi.nlm.nih.gov/PMC4188280/)].
10. Murphy MS, Tayade C, Smith GN. Evidence of inflammation and predisposition toward metabolic syndrome after pre-eclampsia. *Pregnancy Hypertens.* 2015;**5**(4):354-8. doi: [10.1016/j.preghy.2015.09.007](https://doi.org/10.1016/j.preghy.2015.09.007). [PubMed: [26597753](https://pubmed.ncbi.nlm.nih.gov/26597753/)].